Haematology Pathways

Wells score, D-dimer, USS, and anticoagulation for DVT

Vaso-occlusive crisis and acute chest syndrome management in sickle cell disease

Emergency management of febrile neutropaenia — MASCC score and antibiotic escalation

Reversal of warfarin, DOACs, and heparins for major bleeding or emergency surgery

Restrictive transfusion thresholds, consent, and transfusion reactions

Acute Myeloid Leukaemia Presentation clinical pathway.

Tumour Lysis Syndrome clinical pathway.

BSG 2021 — diagnosis (ferritin, transferrin saturation), GI investigation in adults, iron replacement (oral vs IV), recurrence assessment.

BSH 2014 — diagnosis, distinguish pernicious anaemia, urgent treatment if neuro features, B12 replacement schedule, dietary advice.

Diagnosis of exclusion, treatment by platelet count + bleeding, steroid + IVIG first-line, second-line TPO-RA / rituximab.

Diagnose with ISTH criteria, treat underlying cause, blood product replacement, anticoagulation in selected.

MAHA + thrombocytopenia — TTP (ADAMTS13), HUS (Shiga toxin / atypical), drug-induced — urgent plasma exchange for TTP.

Recognise + classify transfusion reactions, immediate management, SHOT reporting, prevention.

CRAB criteria, immunoglobulin / free light chains, bone marrow, imaging, induction therapy.

4Ts pre-test probability, ELISA + functional assay, immediate non-heparin anticoagulant (argatroban / fondaparinux), avoid platelet transfusion.

Recognise pancytopenia + blasts + lymphadenopathy / mediastinal mass, urgent referral, induction chemotherapy.

Distinguish PV / ET / MF — JAK2 mutation, secondary causes, symptom-directed therapy, thrombosis risk reduction.

Indications for testing, panel composition, when NOT to test, anticoagulation duration based on results.

B-symptoms, staging (Ann Arbor / Lugano), excisional biopsy, staging investigations, MDT, treatment by type/stage.